查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1612161

肛門癌市場：按產品、癌症類型和最終用戶 - 2025-2030 年全球預測

Anal Cancer Market by Offering (Drugs, Therapy), Cancer Type (Adenocarcinoma, Melanoma, Squamous Cell Carcinoma), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年肛門癌市場規模為10.6億美元，預計2024年將達10.6億美元，複合年成長率為6.38%，預計2030年將達15.4億美元。

儘管肛門癌是一種相對罕見的疾病，但由於發病率的上升和癌症篩檢意識的提高，它越來越受到人們的關注。該領域的研究和投資範圍包括早期診斷方法、先進的治療性介入和治療後護理，突顯了由於與最終診斷相關的嚴重健康後果和死亡率而需要的必要性。對市場格局的主要研究涉及醫療保健提供者、製藥公司和研究機構，旨在改善診斷和治療通訊協定，最終為包括患者和醫療保健提供者在內的最終用戶塑造市場格局。市場成長受到分子診斷的進步、免疫療法的日益採用以及政府促進癌症研究的支持措施等因素的顯著影響。此外，生活方式的改變導致人類乳突病毒（HPV）等危險因子的盛行率增加，凸顯了有針對性的篩檢計畫和預防策略的潛在機會。

主要市場統計
基準年[2023] 10億美元
預計年份 [2024] 10.6億美元
預測年份 [2030] 15.4億美元
複合年成長率（%） 6.38%

最新的機會在於人工智慧和巨量資料分析的整合，以增強個人化醫療和早期檢測方法。公司可以利用這些技術來開發創新的診斷工具和治療方法，以填補當前市場產品的巨大空白。然而，先進治療方法的高成本、某些人群的認知度低以及新興治療方法的潛在副作用等挑戰阻礙了市場滲透。監管障礙和大規模臨床試驗的需求使產品的快速開發變得更加複雜。

創新成長可能來自對新治療方法的研究，例如 CAR-T 細胞療法和特異性針對 HPV 致癌病毒株的疫苗。此外，生物技術公司和學術機構之間的合作可以加速尖端解決方案的發展。為了挖掘市場潛力，公司正在投資教育宣傳活動，以提高意識並促進早期篩檢，與政策制定者合作簡化核准流程，並減少獲得治療的財務障礙，重點應放在克服成本效益的解決方案上。肛門癌市場仍然充滿活力，鑑於這種成長軌跡以及全球對綜合癌症治療的日益關注，具有重大創新的空間。

市場動態：揭示快速發展的肛門癌市場的關鍵市場洞察

供需的動態交互作用正在改變肛門癌市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 世界各地肛門癌的盛行率正在增加
    • 政府支持肛門癌治療的投資和舉措
  • 市場限制因素
    • 用於治療肛門癌的藥物和治療方法的昂貴
  • 市場機會
    • 核准治療肛門癌的新藥和治療方法
    • 新藥研發投資
  • 市場挑戰
    • 肛門癌藥物和治療方法的長期影響

波特五力戰略工具駕馭肛門癌市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肛門癌市場的外部影響

外部宏觀環境因素在塑造肛門癌市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解肛門癌市場的競爭狀況

對肛門癌市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣肛門癌市場供應商的績效評估

FPNV定位矩陣是評估肛門癌市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了肛門癌市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對肛門癌市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地肛門癌的盛行率正在增加。
      • 政府對肛門癌治療的支持性投資與舉措
    • 抑制因素
      • 用於治療肛門癌的藥物和治療方法的昂貴
    • 機會
      • 核准治療肛門癌的新藥和治療方法
      • 新藥研發投資
    • 任務
      • 肛門癌藥物和治療方法的長期影響
  • 市場區隔分析
    • 我們提供什麼：持續進步和監管支持，以改善肛門癌的治療選擇
    • 癌症類型：鱗狀細胞癌的病例不斷增加，增加了對快速有效的診斷和治療性介入的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章肛門癌市場：透過提供

  • 藥品
    • Carboplatin
    • Cisplatin
    • Fluorouracil
    • 亞葉酸
    • Mitomycin
    • Oxaliplatin
  • 治療
    • 化療
    • 放射治療
    • 標靶治療

第7章依癌症類型分類的肛門癌市場

  • 腺癌
  • 惡性黑色素瘤
  • 鱗狀細胞癌

第8章肛門癌市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第9章美洲肛門癌市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太肛門癌市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的肛門癌市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA 核准納武單抗聯合治療治療進行性尿路上皮癌
    • FDA核准臨時進口中國製造的Cisplatin以解決化療短缺問題
    • Alembic PharmaFluorouracil注射液獲得美國FDA核准
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • ADVANCED MARKER DISCOVERY, SL
  • Alembic Pharmaceuticals Limited
  • Alembic Pharmaceuticals Ltd
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • bioMerieux SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Qilu Pharmaceutical Co. Ltd
  • Regeneron Pharmaceuticals Inc.
  • SANOFI WINTHROP INDUSTRIE
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-CD5A9334D00D

The Anal Cancer Market was valued at USD 1.00 billion in 2023, expected to reach USD 1.06 billion in 2024, and is projected to grow at a CAGR of 6.38%, to USD 1.54 billion by 2030.

Anal cancer, though relatively rare, has been witnessing increased attention due to rising incidence rates and heightened awareness about cancer screenings. The scope of research and investment in this area encompasses early diagnosis methods, advanced therapeutic interventions, and post-treatment care, emphasizing the necessity due to the severe health implications and mortality rates associated with late-stage diagnoses. The primary applications of market insights in anal cancer involve healthcare providers, pharmaceutical companies, and research institutions aiming to refine diagnostics and treatment protocols, ultimately shaping the landscape for end-users including patients and healthcare providers. Market growth is notably influenced by factors such as advancements in molecular diagnostics, increasing adoption of immunotherapy, and supportive government initiatives promoting cancer research. Furthermore, lifestyle changes contributing to a higher prevalence of risk factors such as Human Papillomavirus (HPV) highlight potential opportunities for targeted screening programs and preventative strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 1.00 billion
Estimated Year [2024] USD 1.06 billion
Forecast Year [2030] USD 1.54 billion
CAGR (%) 6.38%

Latest opportunities lie in the integration of AI and big data analytics to enhance personalized medicine and early detection approaches. Companies can leverage these technologies to develop innovative diagnostic tools and treatments, filling notable gaps in current market offerings. Nonetheless, challenges such as the high costs of advanced treatments, limited awareness in certain populations, and potential side effects of emerging therapies hinder market penetration. Regulatory hurdles and the need for extensive clinical trials further complicate rapid product development.

Innovative growth could be driven by research into newer treatment modalities like CAR-T cell therapy and vaccines specifically targeting oncogenic strains of HPV. Additionally, partnerships between biotech firms and academic institutions could fast-track the development of cutting-edge solutions. To capitalize on market potential, businesses should invest in educational campaigns to increase awareness and promote early screening, collaborate with policymakers to streamline approval processes, and focus on cost-effective solutions to overcome financial barriers in treatment access. The anal cancer market remains dynamic, with room for substantial innovation given these growth trajectories and the increasing global focus on comprehensive cancer care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anal Cancer Market

The Anal Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of anal cancer across the globe
    • Supportive government investments and initiatives for anal cancer treatments
  • Market Restraints
    • Expensive nature of drugs and therapies used to treat anal cancer
  • Market Opportunities
    • Approvals for new drugs and therapies for anal cancer treatment
    • Investments in research and development of novel drugs
  • Market Challenges
    • Long-term consequences of anal cancer drugs and therapies

Porter's Five Forces: A Strategic Tool for Navigating the Anal Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anal Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anal Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anal Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anal Cancer Market

A detailed market share analysis in the Anal Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anal Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anal Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anal Cancer Market

A strategic analysis of the Anal Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anal Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ADVANCED MARKER DISCOVERY, S.L., Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, bioMerieux SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Ipsen Pharma, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Qilu Pharmaceutical Co. Ltd, Regeneron Pharmaceuticals Inc., SANOFI WINTHROP INDUSTRIE, Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Anal Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Drugs and Therapy. The Drugs is further studied across Carboplatin, Cisplatin, Fluorouracil, Leucovorin, Mitomycin, and Oxaliplatin. The Therapy is further studied across Chemotherapy, Radiation Therapy, and Targeted Therapy.
  • Based on Cancer Type, market is studied across Adenocarcinoma, Melanoma, and Squamous Cell Carcinoma.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of anal cancer across the globe
      • 5.1.1.2. Supportive government investments and initiatives for anal cancer treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive nature of drugs and therapies used to treat anal cancer
    • 5.1.3. Opportunities
      • 5.1.3.1. Approvals for new drugs and therapies for anal cancer treatment
      • 5.1.3.2. Investments in research and development of novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Long-term consequences of anal cancer drugs and therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Ongoing advancements and regulatory support to improve the therapy options for anal cancer
    • 5.2.2. Cancer Type: Rising cases of squamous cell carcinomas and need for quick and effective diagnostics and treatment interventions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anal Cancer Market, by Offering

  • 6.1. Introduction
  • 6.2. Drugs
    • 6.2.1. Carboplatin
    • 6.2.2. Cisplatin
    • 6.2.3. Fluorouracil
    • 6.2.4. Leucovorin
    • 6.2.5. Mitomycin
    • 6.2.6. Oxaliplatin
  • 6.3. Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Radiation Therapy
    • 6.3.3. Targeted Therapy

7. Anal Cancer Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Adenocarcinoma
  • 7.3. Melanoma
  • 7.4. Squamous Cell Carcinoma

8. Anal Cancer Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Anal Cancer Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anal Cancer Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anal Cancer Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Sanctions Nivolumab Combo for Advanced Urothelial Carcinoma
    • 12.3.2. FDA Approves Temporary Import of Chinese-Made Cisplatin to Address Chemotherapy Shortage
    • 12.3.3. Alembic Pharma Secures USFDA Approval for Fluorouracil Injection
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. ADVANCED MARKER DISCOVERY, S.L.
  • 3. Alembic Pharmaceuticals Limited
  • 4. Alembic Pharmaceuticals Ltd
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Bayer AG
  • 9. bioMerieux SA
  • 10. Boehringer Ingelheim GmbH
  • 11. Bristol-Myers Squibb Company
  • 12. DAIICHI SANKYO COMPANY, LIMITED.
  • 13. Eli Lilly and Company
  • 14. F. Hoffmann-La Roche Ltd
  • 15. GlaxoSmithKline plc.
  • 16. Ipsen Pharma
  • 17. Johnson & Johnson Services, Inc.
  • 18. Merck KGaA
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Qilu Pharmaceutical Co. Ltd
  • 22. Regeneron Pharmaceuticals Inc.
  • 23. SANOFI WINTHROP INDUSTRIE
  • 24. Taj Pharmaceuticals Limited
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANAL CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. ANAL CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANAL CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANAL CANCER MARKET DYNAMICS
  • TABLE 7. GLOBAL ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANAL CANCER MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANAL CANCER MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANAL CANCER MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANAL CANCER MARKET SIZE, BY FLUOROURACIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANAL CANCER MARKET SIZE, BY LEUCOVORIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANAL CANCER MARKET SIZE, BY MITOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANAL CANCER MARKET SIZE, BY OXALIPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANAL CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANAL CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANAL CANCER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. ANAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. ANAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023